Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind study of Mavacamten in symptomatic, obstructive Hypertrophic Cardiomyopathy patients referred for septal reduction therapy (SRT)

Next Previous
Trial Profile

A randomized, double-blind study of Mavacamten in symptomatic, obstructive Hypertrophic Cardiomyopathy patients referred for septal reduction therapy (SRT)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Therapeutic Use

Most Recent Events

  • 09 Nov 2019 New trial record
  • 04 Nov 2019 According to a MyoKardia media release, MyoKardia and the Cleveland Clinic will begin this study in the first half of 2020. The study will be conducted at leading HCM centers that regularly perform surgical myectomy or alcohol septal ablation procedures, with support from the established referral networks at those centers.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top